<?xml version="1.0" encoding="UTF-8"?>
<p>Taken together, these cases illustrate, that after initial proof of concept, it is possible to find second-generation antibodies with more simple routes of delivery and sufficient potency to support relatively infrequent dosing in the field.</p>
